This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Outsourcing Remove Development Remove DNA Related Topics
Reagent Pharma Companies Licensing Clinical Development Protein Regulation Drugs Research Vaccine Vaccination More Related Topics >
article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

SEPTEMBER 29, 2022

CROs offer an established infrastructure to develop, initiate, execute, and progress drug discovery programs towards the clinic. Outsourcing can alleviate unnecessary backlogs and provide access to cutting-edge technologies, giving companies an edge to reach critical discovery milestones in a timely manner.

Reagent 52
Reagent DNA Scientist Drugs 52
article thumbnail

Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal

pharmaphorum

JULY 5, 2021

The CRO “successfully adapted the business to work in the midst of a global pandemic, and supported the development of therapies to combat the COVID-19 pandemic itself,” said Pamplona’s managing partner John Halsted.

Clinical Trials 62
Clinical Trials Clinical Trials Regulation Trials 62
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024